Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
暂无分享,去创建一个
L. Krupp | A. Goodman | A. Blight | Lawrence N Marinucci | Andrew R Blight | R. Schapiro | Andrew D Goodman | Theodore R Brown | Lauren B Krupp | Randall T Schapiro | Steven R Schwid | Ron Cohen | S. Schwid | T. Brown | L. Marinucci | R. Cohen | Ron Cohen
[1] B. Dobkin. Short-distance walking speed and timed walking distance: Redundant measures for clinical trials? , 2006, Neurology.
[2] S. Ozakbas,et al. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis , 2004, Journal of the Neurological Sciences.
[3] C. Bever,et al. The effects of 4‐aminopyridine in multiple sclerosis patients , 1994, Neurology.
[4] D. Mattson,et al. The measurement of ambulatory impairment in multiple sclerosis , 1997, Neurology.
[5] C H Polman,et al. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis , 2006, Multiple sclerosis.
[6] M. Mcdermott,et al. Quantitative assessment of sustained‐release 4‐aminopyridine for symptomatic treatment of multiple sclerosis , 1997, Neurology.
[7] F. A. Davis,et al. 4‐Aminopyridine in multiple sclerosis , 1991, Neurology.
[8] D. Wolfe,et al. Pharmacokinetics of an Immediate‐Release Oral Formulation of Fampridine (4‐Aminopyridine) in Normal Subjects and Patients with Spinal Cord Injury , 2003, Journal of clinical pharmacology.
[9] M. Steuerwald,et al. Carolinas Medical Center , 2004 .
[10] R. Cohen,et al. The extended disability status scale (EDSS) as a predictor of impairments of functional activities of daily living in multiple sclerosis , 1993, Journal of the Neurological Sciences.
[11] Walking capacities in multiple sclerosis measured by global positioning system odometer , 2007, Multiple sclerosis.
[12] J. Fischer,et al. Intrarater and interrater reliability of the MS functional composite outcome measure , 2000, Neurology.
[13] J. Fischer,et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. , 2001, Archives of neurology.
[14] C. Bever,et al. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. , 2006, Pharmacology & therapeutics.
[15] M. Mcdermott,et al. Quantitative functional measures in MS: What is a reliable change? , 2002, Neurology.
[16] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[17] J. Hsieh,et al. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. , 2004, Archives of physical medicine and rehabilitation.
[18] B. Uitdehaag,et al. Aminopyridines for symptomatic treatment in multiple sclerosis. , 2002, The Cochrane database of systematic reviews.
[19] L. Corben,et al. The 25-foot walk velocity accurately measures real world ambulation in Friedreich ataxia , 2007, Neurology.
[20] C. Polman,et al. The effect of 4‐aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo‐controlled, double‐blind, cross‐over study , 1992, Annals of neurology.
[21] J. Norton,et al. The significant change for the Timed 25-Foot Walk in the Multiple Sclerosis Functional Composite , 2000, Multiple sclerosis.
[22] J. De Keyser,et al. Seizures in multiple sclerosis , 2008, Epilepsia.
[23] B. Ashworth. PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS. , 1964, The Practitioner.
[24] A J Thompson,et al. Measuring the impact of MS on walking ability , 2003, Neurology.
[25] H. Albrecht,et al. Day-to-day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameter , 2001, Multiple sclerosis.
[26] A. Cross,et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study , 2007, Multiple sclerosis.
[27] L. Krupp,et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis , 2008, Neurology.
[28] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[29] S. Thesleff,et al. Aminopyridines and similarly acting drugs : effects on nerves, muscles, and synapses : proceedings of a IUPHAR satellite symposium in conjunction with the 8th International Congress of Pharmacology, Paris, France, July 27-29, 1981 , 1982 .